Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder
IRCT20181225042113N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Pregabalin augmentation with Placebo (2 arms). Primary endpoint: Severity of obsession and compulsion after pregabalin treatment. Started Dec 2018; status: completed.
02
Drugs
pregabalin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20181225042113N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181225042113N1.